 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...492493494495496497498499500501502...507508» |
- | Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: Bevacizumab in Extensive Small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2013
P2/3, N=143, Completed, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Active, not recruiting --> Completed
- ||| seribantumab (MM-121) / Elevation Oncology
Enrollment closed: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer (clinicaltrials.gov) - Oct 22, 2013
P2, N=200, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial initiation date: BRCAP-GELTAMO12: Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (clinicaltrials.gov) - Oct 21, 2013
P2, N=127, Recruiting, Sponsor: Grupo Espa
Recruiting --> Active, not recruiting Initiation date: May 2013 --> Oct 2013
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: BRCAP-GELTAMO12: Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (clinicaltrials.gov) - Oct 21, 2013
P2, N=127, Recruiting, Sponsor: Grupo Espa
Initiation date: May 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- New P2 trial, Metastases: Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 20, 2013
P2, N=40, Recruiting, Sponsor: Russian Academy of Medical Sciences
- Enrollment open, Metastases: Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 20, 2013
P2, N=40, Recruiting, Sponsor: Russian Academy of Medical Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Oct 17, 2013
P3, N=2500, Recruiting, Sponsor: Hoffmann-La Roche
- || doxorubicin hydrochloride / Generic mfg.
New P3 trial: TACE as an Adjuvant Therapy After Hepatectomy for HCC (clinicaltrials.gov) - Oct 17, 2013
P3, N=120, Enrolling by invitation, Sponsor: Jia Fan
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 17, 2013
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 16, 2013
P3, N=0, Completed, Sponsor: Leukemia Research Fund
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer (clinicaltrials.gov) - Oct 16, 2013
P3, N=400, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
New P3 trial: A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (clinicaltrials.gov) - Oct 15, 2013
P3, N=162, Recruiting, Sponsor: Hoffmann-La Roche
- New P2 trial, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Oct 15, 2013
P2, N=26, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- Enrollment open, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Oct 15, 2013
P2, N=26, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, New P2 trial: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Oct 8, 2013
P2, N=165, Recruiting, Sponsor: Case Comprehensive Cancer Center
- ||||| Enrollment closed: Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 7, 2013
P3, N=393, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- |||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Combination therapy: PHOENIX: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 3, 2013
P3, N=800, Recruiting, Sponsor: Janssen Research & Development, LLC
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial initiation date, Combination therapy: Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma (clinicaltrials.gov) - Sep 26, 2013
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Aug 2003 --> Dec 2003
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov) - Sep 26, 2013
P2, N=10, Completed, Sponsor: University of Pittsburgh
Initiation date: Aug 2003 --> Dec 2003 Active, not recruiting --> Completed
- | New P4 trial: Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 23, 2013
P4, N=120, Recruiting, Sponsor: Mingzhi Zhang
- | Hepacid (pegargiminase) / Polaris Pharma
New P1 trial, Metastases: Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 22, 2013
P1, N=36, Recruiting, Sponsor: Polaris Group
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
New P2 trial: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Sep 17, 2013
P2, N=47, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Trial completion, Surgery: Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. (clinicaltrials.gov) - Sep 15, 2013
P2, N=0, Completed, Sponsor: European Infant Neuroblastoma Study Group - 1999
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | robatumumab (SCH 717454) / Merck (MSD)
Trial termination: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) (clinicaltrials.gov) - Sep 12, 2013
P2, N=219, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma (clinicaltrials.gov) - Sep 12, 2013
P2, N=0, Completed, Sponsor: European Infant Neuroblastoma Study Group - 1999
Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern. Active, not recruiting --> Completed
- Trial completion, Surgery, Metastases: Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma (clinicaltrials.gov) - Sep 12, 2013
P2, N=0, Completed, Sponsor: European Infant Neuroblastoma Study Group - 1999
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Metastases: Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma (clinicaltrials.gov) - Sep 12, 2013
P2, N=0, Completed, Sponsor: European Infant Neuroblastoma Study Group - 1999
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 12, 2013
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Surgery: Chemotherapy Plus Surgery in Treating Women With Breast Cancer (clinicaltrials.gov) - Sep 12, 2013
P3, N=450, Completed, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Epoch (epoetin beta biosimilar) / Roche
Enrollment change: CATCH: A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL (clinicaltrials.gov) - Sep 10, 2013
P2, N=6, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
Active, not recruiting --> Completed N=18 --> 6
- |||||||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Biomarker, New P3 trial, Metastases: SCHEARLY: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Sep 10, 2013
P3, N=240, Recruiting, Sponsor: Hoffmann-La Roche
- Epoch (epoetin beta biosimilar) / Roche
Trial completion: CATCH: A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL (clinicaltrials.gov) - Sep 10, 2013
P2, N=6, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
N=18 --> 6 Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Biomarker, Trial completion, Metastases: Study to Evaluate Markers of Response in Locally Advanced Breast Cancer (clinicaltrials.gov) - Sep 8, 2013
P2, N=74, Completed, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 4, 2013
P3, N=3054, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Completed --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial termination, Combination therapy: VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=36, Terminated, Sponsor: Vertex Pharmaceuticals Incorporated
Completed --> Active, not recruiting Active, not recruiting --> Terminated
- doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Enrollment change, Combination therapy: VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=36, Terminated, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Terminated N=92 --> 36
- ||||||| aprepitant oral / Generic mfg.
Trial completion: A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) (clinicaltrials.gov) - Sep 3, 2013
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=92 --> 36 Active, not recruiting --> Completed
- zidovudine / Generic mfg.
Clinical: ATLL-HR-01: High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant (clinicaltrials.gov) - Sep 2, 2013
P=N/A, N=20, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Fort-de-France
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, HEOR, Surgery: Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery (clinicaltrials.gov) - Sep 1, 2013
P2, N=40, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 29, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Combination therapy, Metastases: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (clinicaltrials.gov) - Aug 28, 2013
P1/2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=19 --> 26
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Aug 28, 2013
P2, N=50, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
N=19 --> 26 Recruiting --> Active, not recruiting
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial termination, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2013
P2b, N=370, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III.
- Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment change: Study for Treatment of Cancer in Children With Ataxia-telangiectasia (clinicaltrials.gov) - Aug 25, 2013
P=N/A, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. N=30 --> 6
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, Enrollment closed, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 25, 2013
P2, N=100, Active, not recruiting, Sponsor: Genentech
N=30 --> 6 Recruiting --> Active, not recruiting
- Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion: Study for Treatment of Cancer in Children With Ataxia-telangiectasia (clinicaltrials.gov) - Aug 25, 2013
P=N/A, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| thioguanine / Generic mfg.
Enrollment change: Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia (clinicaltrials.gov) - Aug 22, 2013
P3, N=2078, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=1520 --> 2078
- ||||||| dexrazoxane / Generic mfg.
Trial completion: Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - Aug 21, 2013
P3, N=294, Completed, Sponsor: Children's Oncology Group
N=1520 --> 2078 Active, not recruiting --> Completed
- ||||| Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) (clinicaltrials.gov) - Aug 19, 2013
P3, N=1237, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed N=619 --> 1237
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial, Combination therapy: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Aug 18, 2013
P2, N=50, Recruiting, Sponsor: Seattle Genetics, Inc.